Entrada Therapeutics Appoints Biotech Industry Leader Mary Thistle to Its Board of Directors

BOSTON--(BUSINESS WIRE)--Entrada Therapeutics, Inc., a biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics, today announced the appointment of Mary Thistle to its Board of Directors.

Ms. Thistle currently serves as Special Advisor at the Bill & Melinda Gates Medical Research Institute. She has more than 25 years of experience in finance, strategy and business development across a range of therapeutic areas, including a deep background in rare diseases. Ms. Thistle serves on the Board of Directors of Homology Medicines, Enterome SA and Ziopharm Oncology.

"Mary is a recognized leader in the biotechnology industry and has a remarkable track record," stated Dipal Doshi, President and CEO of Entrada Therapeutics. "We look forward to having Mary’s counsel as we leverage our recent $116 million Series B financing to expand our pipeline and aim to bring new and needed treatment options to patients living with devastating diseases."

Prior to joining the Bill & Melinda Gates Medical Research Institute, Ms. Thistle was Chief Operating Officer of Dimension Therapeutics. At Dimension, she oversaw the company’s Series B financing and initial public offering, expanded the pipeline through strategic business development transactions and led the sale of the company to Ultragenyx. Prior to joining Dimension, Ms. Thistle was Senior Vice President, Business Development at Cubist Pharmaceuticals, where she was responsible for multiple acquisitions and assisted in the sale to Merck. She has also held senior level positions at ViaCell in finance, operations and business development and then served as Senior Vice President, Business Development at PerkinElmer after ViaCell was acquired. Ms. Thistle began her career in finance as a Certified Public Accountant.

"Entrada's Endosomal Escape Vehicle platform represents a significant advancement in the field of intracellular biologics," said Ms. Thistle. "The team’s research has the potential to address a wide range of diseases and therapeutic areas, and I’m excited to be able to contribute to Entrada’s mission.”

"We are delighted to welcome Mary to Entrada," commented Kush Parmar, Chairman of Entrada’s Board of Directors. "Her extensive industry experience will help ensure the Board effectively supports the Company’s long-term strategy."

About Entrada Therapeutics

Entrada Therapeutics' mission is to transform the treatment of devastating diseases and improve patients' quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle (EEV)™ platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases. The Company’s novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the field of intracellular biologics.

For more information about Entrada’s pipeline and the broad therapeutic potential of the Company’s EEV™ platform, please visit www.entradatx.com.

Company Contact
Nathan Dowden
Entrada Therapeutics, Inc.
ndowden@entradatx.com

Investor Contact
Bill Slattery, Jr.
Real Chemistry
wslattery@realchemistry.com

Media Contact
Aulani Capuchin
Real Chemistry
acapuchin@realchemistry.com
(559) 355-2673